Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS (CURRENT/OASIS7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00335452
Recruitment Status : Completed
First Posted : June 9, 2006
Results First Posted : October 7, 2010
Last Update Posted : November 18, 2010
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by:
Sanofi

Brief Summary:
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

Condition or disease Intervention/treatment Phase
Acute Coronary Disease Angina Unstable Drug: Clopidogrel Drug: acetylsalicyclic acid (ASA) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25086 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.
Study Start Date : June 2006
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: Clopidogrel high dose treatment regimen + ASA high dose Drug: Clopidogrel
oral administration
Other Names:
  • SR25990
  • Plavix

Drug: acetylsalicyclic acid (ASA)
oral administration

Experimental: Clopidogrel high dose treatment regimen + ASA low dose Drug: Clopidogrel
oral administration
Other Names:
  • SR25990
  • Plavix

Drug: acetylsalicyclic acid (ASA)
oral administration

Active Comparator: Clopidogrel standard treatment regimen + ASA high dose Drug: Clopidogrel
oral administration
Other Names:
  • SR25990
  • Plavix

Drug: acetylsalicyclic acid (ASA)
oral administration

Active Comparator: Clopidogrel standard treatment regimen + ASA low dose Drug: Clopidogrel
oral administration
Other Names:
  • SR25990
  • Plavix

Drug: acetylsalicyclic acid (ASA)
oral administration




Primary Outcome Measures :
  1. First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison [ Time Frame: 30 days ]

    The primary endpoint is the first occurrence of any of the following events:

    • Cardiovascular death (any death with a clear cardiovascular or unknown cause),
    • Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)
    • Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)

    reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC).


  2. First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison [ Time Frame: 30 days ]
  3. First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level [ Time Frame: 30 days ]
  4. First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison [ Time Frame: 30 days ]
    Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC.

  2. Occurrence of Major Bleeding - ASA Dose Level Comparison [ Time Frame: 30 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with acute coronary disease with clinical symptoms and at least electrocardiogram changes or cardiac enzymes elevated

Exclusion Criteria:

  • Use of anticoagulants within 10 days with an international normalized ratio (INR) > 1.5 or planned use during the hospitalisation period
  • Administration of clopidogrel > 75 mg prior to randomization
  • Contraindication to clopidogrel or aspirin
  • Active bleeding or significant risk of bleeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00335452


Locations
Layout table for location information
United States, New Jersey
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States, 08807
Argentina
Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
Australia
sanofi-aventis Australia & New Zealand administrative office
Macquarie Park, Australia
Austria
Sanofi-Aventis Administrative Office
Vienna, Austria
Belgium
Sanofi-Aventis Administrative Office
Diegem, Belgium
Brazil
Sanofi-Aventis Administrative Office
Sao Paulo, Brazil
Bulgaria
Sanofi-Aventis Administrative Office
Sofia, Bulgaria
Canada
Sanofi-Aventis Administrative Office
Laval, Canada
Chile
Sanofi-Aventis Administrative Office
Santiago de Chile, Chile
China
Sanofi-Aventis Administrative Office
Beijing, China
Croatia
Sanofi-Aventis Administrative Office
Zagreb, Croatia
Czech Republic
Sanofi-Aventis Administrative Office
Praha, Czech Republic
Estonia
Sanofi-Aventis Administrative Office
Tallinn, Estonia
Finland
Sanofi-Aventis Administrative Office
Helsinki, Finland
France
Sanofi-Aventis Administrative Office
Paris, France
Germany
Sanofi-Aventis Administrative Office
Berlin, Germany
Greece
Sanofi-Aventis Administrative Office
Athens, Greece
India
Sanofi-Aventis Administrative Office
Mumbai, India
Ireland
Sanofi-Aventis Administrative Office
Dublin, Ireland
Israel
Sanofi-Aventis Administrative Office
Natanya, Israel
Italy
Sanofi-Aventis Administrative Office
Milano, Italy
Korea, Republic of
Sanofi-Aventis Administrative Office
Seoul, Korea, Republic of
Latvia
Sanofi-Aventis Administrative Office
Riga, Latvia
Lithuania
Sanofi-Aventis Administrative Office
Vilnius, Lithuania
Malaysia
Sanofi-Aventis Administrative Office
Kuala Lumpur, Malaysia
Mexico
Sanofi-Aventis Administrative Office
Mexico, Mexico
Netherlands
Sanofi-Aventis Administrative Office
Gouda, Netherlands
Poland
Sanofi-Aventis Administrative Office
Warszawa, Poland
Romania
Sanofi-Aventis Administrative Office
Bucuresti, Romania
Russian Federation
Sanofi-Aventis Administrative Office
Moscow, Russian Federation
Singapore
Sanofi-Aventis Administrative Office
Singapore, Singapore
Slovakia
Sanofi-Aventis Administrative Office
Brastislava, Slovakia
South Africa
Sanofi-Aventis Administrative Office
Midrand, South Africa
Spain
Sanofi-Aventis Admnistrative Office
Madrid, Spain
Sweden
Sanofi-Aventis Administrative Office
Bromma, Sweden
Switzerland
Sanofi-Aventis Administrative Office
Geneva, Switzerland
Turkey
Sanofi-Aventis Administrative Office
Istanbul, Turkey
United Kingdom
Sanofi-Aventis Administrative Office
Guildford, Surrey, United Kingdom
Sponsors and Collaborators
Sanofi
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Shamir MEHTA, MD Hamilton General Hospital, McMaster University, CANADA
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ICD, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00335452    
Other Study ID Numbers: EFC5965
EUDRACT: 2006-000313-38
First Posted: June 9, 2006    Key Record Dates
Results First Posted: October 7, 2010
Last Update Posted: November 18, 2010
Last Verified: November 2010
Keywords provided by Sanofi:
platelet aggregation inhibitors
acute coronary disease
percutaneous coronary
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Ischemia
Clopidogrel
Coronary Disease
Coronary Artery Disease
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs